A depleting antibody toward sca-1 mitigates a surge of CD34(+)/c-kit(+) progenitors and reduces vascular restenosis in a murine vascular injury model.
Vascular restenosis remains a major obstacle to long-term success after vascular intervention. Circulating progenitor cells have been implicated in restenosis, and yet it has remained unclear if these cells, particularly nonendothelial progenitors, have an active role in this pathologic process. We hypothesized that circulating CD34(+)/c-kit(+) progenitors would increase after vascular injury, mirrored by changes in the injury signal, stromal cell-derived factor 1α (sdf1α). We further postulated that an antibody-based depletion would mitigate progenitor surge and, in turn, reduce restenosis in a murine model.



C57BL6 mice underwent wire injury of the femoral artery and were compared with mice with sham surgery and vessel ligation by flow cytometry as well as by sdf1α enzyme-linked immunosorbent assay of peripheral blood. Next, injured C57BL6 mice treated with a depleting antibody toward the progenitor marker sca-1 or with an isotype control were compared in terms of sdf1α as well as enumeration of progenitors. At 28 days, restenosis was quantified between sca-1- and isotype-treated animals.



Wire injury generated an increase in sdf1α as well as a surge of CD34(+)/c-kit(+) progenitors relative to nonsurgical controls (P = .005). Treatment with sca-1 antibody ablated the peripheral surge compared with isotype-treated, injured animals (P = .02), and sca progenitor depletion reduced the 28-day intima to media ratio in a statistically significant fashion compared with either nontreated (P = .04) or isotype-treated (P = .036) animals.



Our study has demonstrated that sca-1 antibody reduces both progenitor surge and vascular restenosis after endoluminal vascular injury in a murine model. This suggests that circulating progenitors play an active role in restenotic disease.
Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa. Electronic address: tillmanbw@upmc.edu.
Bryan W
BW
Tillman
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa.
Jeremy
J
Kelly
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa.
Tara D
TD
Richards
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Veterans Affairs Medical Center, University of Pittsburgh, Pittsburgh, Pa.
Alex F
AF
Chen
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pa; Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pa.
Albert D
AD
Donnenberg
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pa; Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pa.
Vera S
VS
Donnenberg
Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Veterans Affairs Medical Center, University of Pittsburgh, Pittsburgh, Pa.
Edith
E
Tzeng
D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D018952:Antigens, CD34 / Q000378:metabolism*; D000950:Antigens, Ly / Q000276:immunology / Q000378:metabolism; D003251:Constriction, Pathologic; D004195:Disease Models, Animal; D005263:Femoral Artery / Q000187:drug effects* / Q000276:immunology / Q000293:injuries / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006965:Hyperplasia; D008565:Membrane Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D008810:Mice, Inbred C57BL; D058426:Neointima; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors; D057772:Vascular System Injuries / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology
D000906:Antibodies; D018952:Antigens, CD34; D000950:Antigens, Ly; C074650:Ly6a protein, mouse; D008565:Membrane Proteins; D019009:Proto-Oncogene Proteins c-kit